arrow
E

Elaine Cadogan

oncology, r&d, astrazeneca, cambridge cb2 0aa, u.k.
H指数:26
被引数:2,860

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery and Optimization of a Non-Nucleoside-Based Series of Inhibitors of 2′-Deoxynucleoside 5′-Monophosphate Glycosidase (DNPH1)

发现和优化一类非核苷类2′-脱氧核苷-5′-单磷酸糖苷酶(DNPH1)抑制剂

2025-11-060
PRE
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment

ATR抑制剂ceralasertib通过调节肿瘤微环境来增强癌症检查点免疫治疗

2024-02-248
OAAI
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390
2024-02-024
PRE
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK
2022-07-076
OA
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically
2020-01-03123
OAAI
The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
2019-12-1863
OAAI
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
2019-11-07237
OAAI
Reversing PARP inhibitor resistance by targeting the replication stress response
2019-07-010
PRE